不同方法治疗晚期胰腺癌的临床疗效观察

doi:10.3969/j.issn.1002-3070.2009.04.009

摘要/Abstract

摘要： 目的观察三维适形放疗(3D-CRT)联合化疗与单纯化疗治疗晚期胰腺癌的临床疗效和毒副反应。方法我院2000年1月-2006年6月收治的40例晚期不能手术切除的胰腺癌患者。三维适形放疗(3D-CRT)与FH方案交替化疗8例, 三维适形放疗联合GP方案化疗12例, 单纯GP方案化疗20例。三维适形放疗技术应用CT模拟机定位, 3D-TPS进行放射治疗计划设计, 90%等剂量归一1.8Gy-1.9Gy/次, 1次/日, 5次/周, 放射剂量50.4Gy-62.7Gy/5.5-7周。GP方案:健择700mg/m²-1000mg/m², d1, 8, 顺铂20mg/m², d1-3, 单纯化疗组28天为1周期, 连用2-5周期;放化组在放疗前后各1周期。FH方案:5-Fu 500mg/m², HCPT 10mg/m², 第1-5天和第33-38天各1周期, 每次化疗结束后即开始放疗。结果 GP方案单纯化疗组35%出现Ⅲ﹑Ⅳ级血液毒性, 放疗+GP组25%, 放疗+FH组12.5%。放化组疼痛缓解率55%, 放疗+GP组50%, 放疗+FH组62%, 单纯化疗组20%。放化组有效率30%, 放疗+GP组25%, 放疗+FH组37%, 单纯化疗组5%。放化组中位生存期12.0个月, 放疗+FH组12.5个月, 单纯化疗组7个月。放化组1年生存率50%, 放疗+FH组62%, 放疗+GP组41%, GP方案单纯化疗组20%。结论三维适形放疗联合化疗的疼痛缓解率, 有效率高于单纯化疗。三维适形放疗联合化疗较单纯化疗提高了中位生存期和1年生存率, 并且副反应低。放疗+FH方案交替在疼痛的缓解率、有效率、生存期和副反应方面有优于放疗+GP方案的趋势。

关键词: 胰腺癌, 晚期, 三维适形放疗, 化疗

Abstract: Objective To observe the effects and toxicities of the patients with advanced pancreatic cancer treated with 3D-CRT combined with chemotherapy or chemotherapy alone.Methods 40 patients with advanced pancreatic cancer from January, 2000 to June, 2006 were divided into three groups:chemotherapy alone group(20 patients)3D-CRT with FH group(8 patients)3D-CRT with GP group(12 patients).Three dimensional conformal radiotherapy(3D-CRT)carried out as following:CT simulation localization, 3D-TPS, time/fraction schedule:1.8-1.9Gy/F to the 90% isodose line, 1F/D, 5F/W, overall rate:50.4-62.7Gy.Chemotherapy:GP scheme:gemcitabine 700-1000/m2 d1, 8 and Cisplatin 20mg/m²d1-3, GP scheme was applied one cycle at every four weeks and two to five cycles in chemotherapy alone group, and one cycle before and after radiation in 3D-CRT with GP group;FH scheme:5-Fu 500mg/m²and Hcpt 10mg/m² delivered respectively in five days continually, then radiated, when dose achieved 40Gy, the other cycle was given immediately, then radiated again.Results The side effect of 3D-CRT with chemotherapy group was slighter than that of chemotherapy alone group, especially in the FH group.The rate of pain palliation of them were 55% and 20% respectively(P＜0.05)and is higher in the FH group(62%).Five patients experienced partial response and one complete response in the 3D-CRT with chemotherapy group, but partial response was observed in only one patient of the chemotherapy alone group(P＜0.05), and the better effect was observed in the FH group, though without a statistical difference.The median survival from the time of therapy was 12 months in 3D-CRT with chemotherapy group, higher than that of chemotherapy alone group(P＜0.05).The survival rate of 1 year in the former was better, especially in the FH group(P＜0.05).Conclusion The rate of pain palliation was higher in 3D-CRT with chemotherapy group than that of chemotherapy alone group.Better general remission was achieved in the former and the efficacy of the treatment in terms of prolongation of life was proven in the same group, but the side effect was slighter in this group.At the same time, the better effect and slighter toxicity were observed in clinical in the 3D-CRT with FH group than with GP group.

Key words: Pancreatic cancer, Advanced, 3D-CRT, Chemotherapy

中图分类号:

R735.9

栾瑾微, 尤庆山. 不同方法治疗晚期胰腺癌的临床疗效观察[J]. 实用肿瘤学杂志, 2009, 23(4): 328-331.

LUAN Jinwei, YOU Qingshan. Effects of 3D-CRT combined with chemotherapy and chemotherapy alone in advanced pancneatic cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 328-331.

[1]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	梁虹, 李奇, 王耀先, 靳红, 王铜, 王亚楠, 段雅妮, 宋敏. 宫颈癌化疗心血管毒性预防的间断时间序列试验[J]. 实用肿瘤学杂志, 2019, 33(2): 134-138.
[4]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[5]	秦岚群, 邹征云. 恶性黑色素瘤化疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 167-172.
[6]	罗干, 易超, 依马木买买提江·阿布拉, 徐林, 尹继炜, 丁伟. Notch信号通路在胰腺癌中的表达及其作用研究[J]. 实用肿瘤学杂志, 2019, 33(1): 1-7.
[7]	常晓霞综述, 宋冰冰, 刘家仁审校. 植物化学物增加肿瘤细胞对化疗药物敏感性的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 67-72.
[8]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[9]	张夏兰, 沈夕坤, 黄玉宇. 营养风险筛查2002在晚期肿瘤患者营养状况筛查中的运用[J]. 实用肿瘤学杂志, 2018, 32(3): 229-233.
[10]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[11]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[12]	杨文娟, 余静, 黄朝, 张俊红, 谢丛华. 化疗早期重度粒细胞下降与小细胞肺癌预后相关性分析[J]. 实用肿瘤学杂志, 2018, 32(1): 19-24.
[13]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[14]	梁语丝, 谭永刚, 邹华伟审校. 低剂量化疗作用机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 538-542.
[15]	石峰,于雁. 节拍化疗通过影响血管形成及免疫系统抑制肿瘤细胞生长的机制[J]. 实用肿瘤学杂志, 2017, 31(4): 316-320.

不同方法治疗晚期胰腺癌的临床疗效观察

Effects of 3D-CRT combined with chemotherapy and chemotherapy alone in advanced pancneatic cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价